ICCM News & Events

IceCure Medical highlighted the growing international interest in its ProSense system in Brazil at the Simposio de Radiologia Intervencionista em Oncologia. "IceCure's ProSense(TM) holds Agencia Nacional de Vigilancia Sanitaria regulatory approval in Brazil and is experiencing growing commercial expansion in the country. We believe the recent U.S. Food and Drug Administration's marketing authorization for early-stage, low-risk breast cancer has provided significant tailwind, boosting awareness and interest among Brazilian physicians and institutions", commented IceCure CEO, Eyal Shamir "Commercial procedures are already being performed, including for breast, lung, kidney cancer and musculoskeletal tumors", Shamir continued.

This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.5M ordinary shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.